SOLIGENIX, INC. Contract Liability (Deferred Revenue)
SOLIGENIX, INC. (SNGX) had Contract Liability (Deferred Revenue) of $100.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2022-11-10
- 2022-09-30: Contract with Customer, Liability, Current $100.00K.
- 2022-06-30: Contract with Customer, Liability, Current $100.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |